Drug Profile
Research programme: triple reuptake inhibitors - Sepracor
Latest Information Update: 28 Oct 2010
Price :
$50
*
At a glance
- Originator Sepracor
- Class
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 13 Oct 2010 Discontinued - Preclinical for Anxiety disorders in USA (unspecified route)
- 13 Oct 2010 Discontinued - Preclinical for Depression in USA (unspecified route)
- 20 Oct 2009 Sepracor has been acquired by Dainippon Sumitomo Pharma